European Medicines Agency renews Marketing Authorisation for ChondroCelect

Regulated information
1 July, 2014

European Medicines Agency renews Marketing Authorisation for ChondroCelect

Leuven (BELGIUM) - 1 July, 2014 -TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that the Committee for Medicinal Products for Human Use (CHMP) has renewed for an additional five years its marketing authorisation for ChondroCelect in all of the 31 countries of the European Union (EU) and European Economic Area (EEA).

"ChondroCelect was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA) in October 2009, and it is the first ATMP to have its marketing authorisation renewed. The decision confirms the proven capability of TiGenix to develop and bring cell therapy products of real medical benefit to patients," said Maria Pascual, Vice-President of Clinical Operations and Regulatory Affairs at TiGenix. "After five years of post-commercialisation activity, and with an accumulated experience of over 1,000 patients, the CHMP confirms with its renewal that the benefit-risk balance remains positive for ChondroCelect."

Legislation of the European Union (EU) requires manufacturers of prescription medicines to apply for renewal of the marketing authorisation after a five year term and based on a re-evaluation of mainly safety data, only products that continue to have a positive risk-benefit ratio have their marketing authorisation renewed.

In parallel to its commercialisation efforts, TiGenix is conducting an open-label, multicentre, non-interventional study in patients treated with ChondroCelect for single symptomatic cartilage lesions of the knee of at least 2cm² and symptom onset of less than 3 years. The results from an interim analysis  of 153 patients in this study indicate statistically and clinically significant improvement in all KOOS¹ subscale scores versus baseline. These data from treatment in daily clinical practice confirm the positive results from previous randomised clinical trials.

¹ KOOS stands for Knee Injury and Osteoarthritis Outcome Score

For more information

For TiGenix:
Richard Simpson
Senior Consultant, Comfi sprl
T: [phone]
[e-mail]

About ChondroCelect

ChondroCelect, indicated for cartilage repair in the knee, was the first cell-based product approved in Europe that successfully completed the entire development track from research through clinical development to European approval and received European Marketing Authorisation in October 2009 as the first Advanced Therapy Medicinal Product. It was approved for reimbursement in Belgium in February 2011, in the Netherlands in June 2012 (retroactively to January 2011) and in Spain in March 2013. Effective 1 June 2014, the company has entered into a distribution agreement with Sobi (Swedish Orphan Biovitrum AB) for the exclusive marketing and distribution rights with respect to ChondroCelect in Europe (excluding Finland, where TiGenix has a pre-exisiting distribution agreement with Finnish Red Cross Blood Services), the Middle East and North Africa.